Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC

References

• van Gestel YRBM, Thomassen I, Lemmens VEPP, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40(8):963–969. doi:10.1016/j.ejso.2013.10.00124183168
   PubMed Web of Science ®Google Scholar
• Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a Population-Based Study. Int J Cancer. 2011;128(11):2717–2725. doi:10.1002/ijc.2559620715167
   PubMed Web of Science ®Google Scholar
• Klaver YLB, Lemmens VEPP, Creemers GJ, Rutten HJT, Nienhuijs SW, de Hingh IHJT. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22(10):2250–2256. doi:10.1093/annonc/mdq76221345939
   PubMed Web of Science ®Google Scholar
• Razenberg LGEM, Lemmens VEPP, Verwaal VJ, et al. Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a Population-Based Study. Eur J Cancer. 2016;65:113–120. doi:10.1016/j.ejca.2016.07.00227497343
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• van der Geest LGM, Lam-Boer J, Koopman M, Verhoef C, Elferink MAG, de Wilt JHW. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457–465. doi:10.1007/s10585-015-9719-025899064
   PubMed Web of Science ®Google Scholar
• van Gestel YRBM, de Hingh IHJT, van Herk-sukel MPP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38(4):448–454. doi:10.1016/j.canep.2014.04.00424841870
   PubMed Web of Science ®Google Scholar
• Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25(3):651–657. doi:10.1093/annonc/mdt59124504447
   PubMed Web of Science ®Google Scholar
• Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Colorectal Dis. 2014;16(5):359–367. doi:10.1111/codi.1255224410859
   PubMed Web of Science ®Google Scholar
• Bastiaenen VP, Aalbers AGJ, Arjona-Sánchez A, et al. Risk of metachronous peritoneal metastases in patients with pT4a versus pT4b colon cancer: an International Multicentre Cohort Study. Eur J Surg Oncol. 2021. doi:10.1016/j.ejso.2021.05.009
   Web of Science ®Google Scholar
• Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies results of the EVOCAPE 1 Multicentric Prospective Study. Cancer. 2000;88(2):358–363. doi:10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O10640968
   PubMed Web of Science ®Google Scholar
• Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–1550. doi:10.1046/j.1365-2168.2002.02274.x12445064
   PubMed Web of Science ®Google Scholar
• Chu DZJ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritioneal carcinomatosis in nongynecologic malignancy. A Prospective Study of prognostic factors. Cancer. 1989;63(2). doi:10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Cervantes A, Nordlinger B, Arnold D; The ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii1–iii9. doi:10.1093/annonc/mdu26025190710
   PubMed Web of Science ®Google Scholar
• Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17(12):1709–1719. doi:10.1016/S1470-2045(16)30500-927743922
   PubMed Web of Science ®Google Scholar
• Klaver YLB, Simkens LHJ, Lemmens VEPP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7):617–623. doi:10.1016/j.ejso.2012.03.00822572106
   PubMed Web of Science ®Google Scholar
• Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21(8):2608–2614. doi:10.1245/s10434-014-3647-024668148
   PubMed Web of Science ®Google Scholar
• Blazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–5351. doi:10.1200/JCO.2008.17.529918936472
   PubMed Web of Science ®Google Scholar
• Chan G, Hassanain M, Chaudhury P, et al. Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. HPB. 2010;12(4):277–284. doi:10.1111/j.1477-2574.2010.00170.x20590898
   PubMed Web of Science ®Google Scholar
• Razenberg LGEM, van Gestel YRBM, Creemers GJ, Verwaal VJ, Lemmens VEPP, de Hingh IHJT. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. Eur J Surg Oncol. 2015;41(4):466–471. doi:10.1016/j.ejso.2015.01.01825680955
   PubMed Web of Science ®Google Scholar
• Simkens GA, Razenberg LG, Lemmens VE, Rutten HJ, Creemers GJ, de Hingh IH. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Eur J Surg Oncol. 2016;42(6):794–800. doi:10.1016/j.ejso.2016.03.01427055946
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):20. doi:10.1200/JCO.2003.04.18712506165
   PubMed Web of Science ®Google Scholar
• Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–266. doi:10.1016/S1470-2045(20)30599-433476595
   PubMed Web of Science ®Google Scholar
• Nagourney RA, Evans S, Tran PH, Nagourney AJ, Sugarbaker PH. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. Eur J Surg Oncol. 2020;47(4):738–742. doi:10.1016/j.ejso.2020.09.01733004272
   PubMed Web of Science ®Google Scholar
• Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res. 2017;9:259–266. doi:10.2147/CMAR.S11956928721098
   PubMed Web of Science ®Google Scholar
• Devilee RA, Simkens GA, van Oudheusden TR, et al. Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2841–2848. doi:10.1245/s10434-016-5214-327044447
   PubMed Web of Science ®Google Scholar
• Rovers KP, Bakkers C, Simkens GAAM, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, Phase II-III, randomised, Superiority Study (CAIRO6). BMC Cancer. 2019;19(1). doi:10.1186/s12885-019-5545-0
   PubMed Web of Science ®Google Scholar
• Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases a meta-analysis. Ann Surg. 2016;263(6):1102–1111. doi:10.1097/SLA.000000000000159326756756
   PubMed Web of Science ®Google Scholar
• Steffen T, Eden J, Bijelic L, et al. Patient selection for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer: consensus on decision making among international experts. Clin Colorectal Cancer. 2020;19(4):277–284. doi:10.1016/j.clcc.2020.06.01032912822
   PubMed Web of Science ®Google Scholar
• Narasimhan V, Tan S, Kong J, et al. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis. Colorectal Dis. 2020;22(11):1482–1495. doi:10.1111/codi.1500332027455
   PubMed Web of Science ®Google Scholar
• Spiliotis JD, Halkia E, Boumis VA, Vassiliadou DT, Pagoulatou A, Efstathiou E. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol. 2014;2014:1–5. doi:10.1155/2014/987475
   Google Scholar
• Simkens GA, van Oudheusden TR, Nieboer D, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. Ann Surg Oncol. 2016;23(13):4214–4221. doi:10.1245/s10434-016-5211-627027308
   PubMed Web of Science ®Google Scholar
• Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a Multicentric French Study. J Clin Oncol. 2010;28(1):63–68. doi:10.1200/JCO.2009.23.928519917863
   PubMed Web of Science ®Google Scholar
• Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a Multi-Institutional Study. J Clin Oncol. 2004;22(16):3284–3292. doi:10.1200/JCO.2004.10.01215310771
   PubMed Web of Science ®Google Scholar
• Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019;3(5):585–594. doi:10.1002/bjs5.5017931592510
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Res Treat. 1996;82:359–374. doi:10.1007/978-1-4613-1247-5_23
   Google Scholar
• Birgisson H, Enblad M, Artursson S, Ghanipour L, Cashin P, Graf W. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2020;46(12):2283–2291. doi:10.1016/j.ejso.2020.07.03932873455
   PubMed Web of Science ®Google Scholar
• Bushati M, Rovers KP, Sommariva A, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the peritoneal surface oncology group international (PSOGI). Eur J Surg Oncol. 2018;44(12):1942–1948. doi:10.1016/j.ejso.2018.07.00330075978
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91(6):739–746. doi:10.1002/bjs.451615164445
   PubMed Web of Science ®Google Scholar
• Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327–333. doi:10.1245/s10434-008-0234-219050972
   PubMed Web of Science ®Google Scholar
• van ’T Sant I, Engbersen MP, Bhairosing PA, et al. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur Radiol. 2020;30(6):3101–3112. doi:10.1007/s00330-019-06524-x32065287
   PubMed Web of Science ®Google Scholar
• van Oudheusden TR, Braam HJ, Luyer MDP, et al. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis. Ann Surg Oncol. 2015;22(4):1236–1242. doi:10.1245/s10434-014-4148-x25319584
   PubMed Web of Science ®Google Scholar
• Leimkühler M, de Haas RJ, Pol VEH, et al. Adding diagnostic laparoscopy to computed tomography for the evaluation of peritoneal metastases in patients with colorectal cancer: a Retrospective Cohort Study. Surg Oncol. 2020;33:135–140. doi:10.1016/j.suronc.2020.02.01032561078
   PubMed Web of Science ®Google Scholar
• van ’T Sant I, van Eden WJ, Engbersen MP, et al. Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. Br J Surg. 2019;106(4):491–498. doi:10.1002/bjs.1098930353920
   PubMed Web of Science ®Google Scholar
• Engbersen MP, Aalbers AGJ, Van‘t Sant-jansen I, et al. Extent of peritoneal metastases on preoperative DW-MRI is predictive of disease-free and overall survival for CRS/HIPEC candidates with colorectal cancer. Ann Surg Oncol. 2020;27(9):3516–3524. doi:10.1245/s10434-020-08416-732239338
   PubMed Web of Science ®Google Scholar
• Kozman MA, Fisher OM, Valle SJ, Alzahrani N, Liauw W, Morris DL. The volume-time index (VTI) is prognostic in patients with colorectal cancer peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy. Am J Surg. 2020;219(1):58–64. doi:10.1016/j.amjsurg.2019.03.02330982572
   PubMed Web of Science ®Google Scholar
• Hentzen JEKR, van der Plas WY, Kuipers H, et al. Delta peritoneal cancer index (ΔPCI): a new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases. Eur J Surg Oncol. 2020;46(4):590–599. doi:10.1016/j.ejso.2019.11.51531806520
   PubMed Web of Science ®Google Scholar
• Simkens GA, van Oudheusden TR, Braam HJ, et al. Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a Matched Case Control Study. J Surg Oncol. 2016;113(5):548–553. doi:10.1002/jso.2416927110701
   PubMed Web of Science ®Google Scholar
• Tonello M, Sommariva A, Pirozzolo G, Mattara G, Pilati P. Colic and rectal tumors with peritoneal metastases treated with cytoreductive surgery and HIPEC: one homogeneous condition or two different diseases? A systematic review and meta-analysis. Eur J Surg Oncol. 2019;45(11):2003–2008. doi:10.1016/j.ejso.2019.06.02031217079
   PubMed Web of Science ®Google Scholar
• van Oudheusden TR, Braam HJ, Nienhuijs SW, et al. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol. 2015;111(2):237–242. doi:10.1002/jso.2378425195780
   PubMed Web of Science ®Google Scholar
• Esquivel J, Lowy AM, Markman M, et al. The American society of peritoneal surface malignancies (ASPSM) multiinstitution evaluation of the peritoneal surface disease severity score (PSDSS) in 1013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(13):4195–4201. doi:10.1245/s10434-014-3798-z24854493
   PubMed Web of Science ®Google Scholar
• El-Nakeep S, Rashad N, Oweira H, et al. Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review. Expert Rev Gastroenterol Hepatol. 2017;11(3):249–258. doi:10.1080/17474124.2017.128458628099818
   PubMed Web of Science ®Google Scholar
• Flood M, Das A, Soucisse M, et al. Synchronous liver resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases: a systematic review and meta-analysis running title surgical management of CRPM and CRLM. Dis Colon Rectum. 2021;Publish Ahead of Print. doi:10.1097/DCR.0000000000002027
   Web of Science ®Google Scholar
• de Cuba EMV, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases. Systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2013;39(4):321–327. doi:10.1016/j.ctrv.2012.11.00323244778
   PubMed Web of Science ®Google Scholar
• Elias D, Faron M, Goéré D, et al. A simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. Ann Surg Oncol. 2014;21(6):2052–2058. doi:10.1245/s10434-014-3506-z24499829
   PubMed Web of Science ®Google Scholar
• Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res Pract. 2020;13(5):184–198. doi:10.14740/gr1167
   Web of Science ®Google Scholar
• Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13–21. doi:10.1093/annonc/mdu37825115304
   PubMed Web of Science ®Google Scholar
• Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96(8):1166–1169. doi:10.1038/sj.bjc.660368517375050
   PubMed Web of Science ®Google Scholar
• Modest DP, Ricard I, Heinemann V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016;27(9):1746–1753. doi:10.1093/annonc/mdw26127358379
   PubMed Web of Science ®Google Scholar
• Lipsyc MD, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6(6):645–649. doi:10.3978/j.issn.2078-6891.2015.04526697197
   PubMed Web of Science ®Google Scholar
• Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175–1183. doi:10.1002/bjs.987026206254
   PubMed Web of Science ®Google Scholar
• Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D, et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. Ann Surg Oncol. 2019;26(8):2595–2604. doi:10.1245/s10434-019-07378-931111351
   PubMed Web of Science ®Google Scholar
• Morgan Z, Chow BE, Strong EA, et al. RAS mutation status confers prognostic relevance in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. J Surg Res. 2019;240:130–135. doi:10.1016/j.jss.2019.02.05030928770
   PubMed Web of Science ®Google Scholar
• Schneider MA, Eden J, Pache B, et al. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268(5):845–853. doi:10.1097/SLA.000000000000289930303876
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Niger M, et al. Prognostic impact of primary side and RAS/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases. Ann Surg Oncol. 2020. doi:10.1245/s10434-020-09161-7
   Web of Science ®Google Scholar
• Gillern SM, Chua TC, Stojadinovic A, Esquivel J. KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. Am J Clin Oncol. 2010;33(5):5. doi:10.1097/COC.0b013e3181b4b160
   Web of Science ®Google Scholar
• Massalou D, Benizri E, Chevallier A, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213(2):377–387. doi:10.1016/j.amjsurg.2016.03.00827816197
   PubMed Web of Science ®Google Scholar
• Passot G, Kim BJ, Glehen O, et al. Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: does site of metastases matter? Ann Surg Oncol. 2018;25(1):179–187. doi:10.1245/s10434-017-6141-729071660
   PubMed Web of Science ®Google Scholar
• Graf W, Cashin PH, Ghanipour L, et al. Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendical peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 2020;27(1):293–300. doi:10.1245/s10434-019-07452-231571052
   PubMed Web of Science ®Google Scholar
• Bach S, Sluiter NR, Beagan JJ, et al. Circulating tumor DNA analysis: clinical implications for colorectal cancer patients. A systematic review. JNCI Cancer Spectr. 2019;3(3). doi:10.1093/jncics/pkz042
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Yoshino T. Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer. Oncologist. 2018;23(11):1310–1318. doi:10.1634/theoncologist.2017-062129700206
   PubMed Web of Science ®Google Scholar
• Beagan JJ, Sluiter NR, Bach S, et al. Circulating tumor DNA as a preoperative marker of recurrence in patients with peritoneal metastases of colorectal cancer: a Clinical Feasibility Study. J Clin Med. 2020;9(6):1738. doi:10.3390/jcm9061738
   PubMed Web of Science ®Google Scholar
• Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124–1131. doi:10.1001/jamaoncol.2019.052831070691
   PubMed Web of Science ®Google Scholar
• Vidal J, Muinelo L, Dalmases A, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28(6):1325–1332. doi:10.1093/annonc/mdx12528419195
   PubMed Web of Science ®Google Scholar
• Osumi H, Shinozaki E, Takeda Y, et al. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Med. 2019;8(1):408–417. doi:10.1002/cam4.191330575318
   PubMed Web of Science ®Google Scholar
• Van’t Erve I, Rovers KP, Constantinides A, et al. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid. J Pathol Clin Res. 2021;7(3):203–208. doi:10.1002/cjp2.20733635598
   PubMedGoogle Scholar
• Lavotshkin S, Jalas JR, Torisu-Itakura H, et al. Immunoprofiling for prognostic assessment of colon cancer: a novel complement to ultrastaging. J Gastrointest Surg. 2015;19(6):999–1006. doi:10.1007/s11605-015-2759-625808375
   PubMed Web of Science ®Google Scholar
• Galon J. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):5795. doi:10.1126/science.1129139
   Web of Science ®Google Scholar
• Flaherty DC, Lavotshkin S, Jalas JR, et al. Prognostic utility of immunoprofiling in colon cancer: results from a prospective, multicenter nodal ultrastaging trial. J Am Coll Surg. 2016;223(1):134–140. doi:10.1016/j.jamcollsurg.2016.03.00327282965
   PubMed Web of Science ®Google Scholar
• Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a Prognostic and Accuracy Study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X29754777
   PubMed Web of Science ®Google Scholar
• Garland-Kledzik M, Uppal A, Naeini YB, et al. Prognostic impact and utility of immunoprofiling in the selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC). J Gastrointest Surg. 2020;25(1):233–240. doi:10.1007/s11605-020-04886-y33269456
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356. doi:10.1038/nm.396726457759
   PubMed Web of Science ®Google Scholar
• Song N, Pogue-Geile KL, Gavin PG, et al. Clinical outcome from oxaliplatin treatment in stage II/III colon cancer according to intrinsic subtypes: secondary analysis of NSABP C-07/NRG oncology randomized clinical trial. JAMA Oncol. 2016;2(9):1162–1169. doi:10.1001/jamaoncol.2016.231427270348
   PubMed Web of Science ®Google Scholar
• Trinh A, Trumpi K, De Sousa E Melo F. Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. Clin Cancer Res. 2017;23(2):387–398. doi:10.1158/1078-0432.CCR-16-068027459899
   PubMed Web of Science ®Google Scholar
• Ubink I, Van eden WJ, Snaebjornsson P, et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg. 2018;105(2):e204–e211. doi:10.1002/bjs.1078829341165
   PubMed Web of Science ®Google Scholar
• Pelz JOW, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9–15. doi:10.1002/jso.2116918937291
   PubMed Web of Science ®Google Scholar
• Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American society of peritoneal surface malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779–785. doi:10.1002/jso.2372825088304
   PubMed Web of Science ®Google Scholar
• Ng JL, Ong WS, Chia CS, Tan GHC, Soo KC, Teo MCC. Prognostic relevance of the peritoneal surface disease severity score compared to the peritoneal cancer index for colorectal peritoneal carcinomatosis. Int J Surg Oncol. 2016;2016:1–7. doi:10.1155/2016/2495131
   Google Scholar
• Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an Observational Cohort Study. Ann Surg. 2012;256(6):1078–1083. doi:10.1097/SLA.0b013e318254f28122580940
   PubMed Web of Science ®Google Scholar
• Cashin PH, Graf W, Nygren P, Mahteme H. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(13):4183–4189. doi:10.1245/s10434-013-3204-223975316
   PubMed Web of Science ®Google Scholar
• Demey K, Wolthuis A, de Buck van Overstraeten A, et al. External validation of the prognostic nomogram (COMPASS) for patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2017;24(12):3604–3608. doi:10.1245/s10434-017-6042-928895112
   PubMed Web of Science ®Google Scholar
• Enblad M, Ghanipour L, Cashin PH. Prognostic scores for colorectal cancer with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2018;34(8):1390–1395. doi:10.1080/02656736.2018.146466829695209
   PubMed Web of Science ®Google Scholar
• Kozman MA, Fisher OM, Rebolledo BAJ, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol. 2018;117(4):725–736. doi:10.1002/jso.2491129266235
   PubMed Web of Science ®Google Scholar